Oral selective estrogen receptor degraders (SERDs) in hormone receptor-positive HER2-negative metastatic breast cancer after progression with CDK4/6 inhibitors

Oral selective estrogen receptor degraders (SERDs) show promise for HR+, HER2-negative metastatic breast cancer patients who have progressed after CDK4/6 inhibitor treatment, especially those with ESR1 mutations. This review article, published in Expert Review of Anticancer Therapy, explores key clinical trials involving oral SERDs in this patient population, including the EMERALD trial, which led to the approval of the first oral SERD elacestrant.  Access the full article Abstract Introduction Hormone receptor-positive (HR+), HER2-negative metastatic breast cancer (mBC) remains a prevalent and challenging disease. Endocrine therapy (ET) combined with CDK4/6 inhibitors is the first-line standard of care, yet resistance mechanisms, including ESR1 mutations,...